Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) Accumulated Depreciation & Amortization (2016 - 2025)

United Therapeutics' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $85.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 18.07% year-over-year to $85.6 million; the TTM value through Dec 2025 reached $85.6 million, up 18.07%, while the annual FY2025 figure was $85.6 million, 18.07% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $85.6 million at United Therapeutics, up from $62.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $85.6 million in Q4 2025 and bottomed at $12.5 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $37.7 million (2021), against an average of $38.4 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization dropped 0.4% in 2021 before it soared 36.28% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $49.9 million in 2021, then grew by 2.81% to $51.3 million in 2022, then grew by 3.7% to $53.2 million in 2023, then soared by 36.28% to $72.5 million in 2024, then grew by 18.07% to $85.6 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Accumulated Depreciation & Amortization are $85.6 million (Q4 2025), $62.8 million (Q3 2025), and $40.9 million (Q2 2025).